biotech · Breast Cancer · Advanced Breast Cancer · PBYI
PUMA BIOTECHNOLOGY
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology is a biotech organization headquartered in Los Angeles, USA. It trades on NYSE under ticker PBYI. Primary therapeutic focus areas include Breast Cancer, Advanced Breast Cancer, HER2+ Metastatic Breast
10880 Wilshire Blvd, Los Angeles, CA 90024, US HQ
2010 Founded
257 Employees
Public company Type
PBYI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 10880 Wilshire Blvd, Los Angeles, CA 90024, US
- Founded
- 2010
- Employees
- 257
- Programs
- 40
- Drugs
- 23
- Patents
- 1
neratinib
Phase 3 · small molecule · HER2+ Metastatic Breast Cancer (MBC)
neratinib for HER2+ Metastatic Breast Cancer (MBC) is a Phase 3 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Internal code PUMA-NER-1301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- PUMA BIOTECHNOLOGY, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- HER2+ Metastatic Breast Cancer (MBC)
- Status
- completed
- Trials
- 1